

ATRION CORP
Form 10-Q
May 05, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

Quarterly Report Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2016

or
 Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Transition Period from to

Commission File Number 0-10763

Atrion Corporation
(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation or
Organization)

63-0821819
(I.R.S. Employer
Identification No.)

One Allentown Parkway, Allen, Texas 75002
(Address of Principal Executive
Offices) (Zip Code)

(972) 390-9800
(Registrant's Telephone Number, Including Area Code)

Indicate by check whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Number of Shares Outstanding

Edgar Filing: ATRION CORP - Form 10-Q

| Title of Each Class | at |
|--|-----------------------------|
| Common stock, Par Value \$0.10 per share | April 20, 2016 1,820,402 |

ATRION CORPORATION AND SUBSIDIARIES

TABLE OF CONTENTS

| | | |
|---------------|--|----|
| PART I. | Financial Information | 2 |
| Item 1. | Financial Statements | |
| | Consolidated Statements of Income (Unaudited) For the Three months Ended March 31, 2016 and 2015 | 3 |
| | Consolidated Statements of Comprehensive Income (Unaudited) For the Three months Ended March 31, 2016 and 2015 | 4 |
| | Consolidated Balance Sheets (Unaudited) March 31, 2016 and December 31, 2015 | 5 |
| | Consolidated Statements of Cash Flows (Unaudited) For the Three months Ended March 31, 2016 and 2015 | 6 |
| | Consolidated Statement of Changes in Stockholders' Equity (Unaudited) March 31, 2016 and December 31, 2015 | 7 |
| | Notes to Consolidated Financial Statements (Unaudited) | 8 |
| Item 2. | Management's Discussion and Analysis of Financial Condition and Results of Operations | 12 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 16 |
| Item 4. | Controls and Procedures | 16 |
| PART II. | Other Information | 16 |
| Item 1. | Legal Proceedings | 16 |
| Item 1A. | Risk Factors | 16 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 17 |
| Item 6. | Exhibits | 17 |
| SIGNATURES | | 18 |
| Exhibit Index | | 19 |

PART I
FINANCIAL INFORMATION

2

Item 1. Financial Statements

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

| | Three Months Ended March 31, | |
|---|---|----------|
| | 2016 | 2015 |
| | (in thousands, except per share amounts) | |
| Revenues | \$36,215 | \$38,324 |
| Cost of goods sold | 18,650 | 19,800 |
| Gross profit | 17,565 | 18,524 |
| Operating expenses: | | |
| Selling | 1,735 | 1,520 |
| General and administrative | 3,949 | 3,958 |
| Research and development | 1,416 | 1,560 |
| | 7,100 | 7,038 |
| Operating income | 10,465 | 11,486 |
| Interest income | 123 | 177 |
| Other income (expense), net | (345) | - |
| Income before provision for income taxes | 10,243 | 11,663 |
| Provision for income taxes | (3,298) | (4,061) |
| Net income | \$6,945 | \$7,602 |
| Net income per basic share | \$3.81 | \$4.05 |
| Weighted average basic shares outstanding | 1,823 | 1,875 |
| Net income per diluted share | \$3.76 | \$4.01 |
| Weighted average diluted shares outstanding | 1,849 | 1,895 |
| Dividends per common share | 0.90 | 0.75 |

The accompanying notes are an integral part of these statements.

ATRION CORPORATION
 CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
 (Unaudited)

Three Months Ended
 March 31,
 2016 2015
 (In thousands)

| | | |
|--|---------|---------|
| Net Income | \$6,945 | \$7,602 |
| Other Comprehensive income (loss): | | |
| Unrealized income (loss) on investments, net of tax benefit of \$37 in 2016 and net of tax expense of \$62 in 2015 | (68 |) 114 |
| Comprehensive Income | \$6,877 | \$7,716 |

The accompanying notes are an integral part of these statements.

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)

| Assets | March 31, 2016 | December 31, 2015 |
|---|-------------------|-------------------------|
| | (in thousands) | |
| Current assets: | | |
| Cash and cash equivalents | \$27,947 | \$28,346 |
| Short-term investments | 39 | 44 |
| Accounts receivable | 21,717 | 16,620 |
| Inventories | 30,468 | 29,771 |
| Prepaid expenses and other current assets | 1,372 | 2,934 |
| Deferred income taxes | 580 | 580 |
| | 82,123 | 78,295 |
| Long-term investments | 11,092 | 9,866 |
| Property, plant and equipment | 153,660 | 150,807 |
| Less accumulated depreciation and amortization | 89,548 | 87,493 |
| | 64,112 | 63,314 |
| Other assets and deferred charges: | | |
| Patents | 2,131 | 2,193 |
| Goodwill | 9,730 | 9,730 |
| Other | 999 | 938 |
| | 12,860 | 12,861 |
| Total assets | \$170,187 | \$164,336 |
| Liabilities and Stockholders' Equity | | |
| Current liabilities: | | |
| Accounts payable and accrued liabilities | \$8,500 | \$8,987 |
| Accrued income and other taxes | 2,538 | 329 |
| | 11,038 | 9,316 |
| Line of credit | -- | -- |
| Other non-current liabilities | 10,597 | 10,922 |
| Stockholders' equity: | | |
| Common stock, par value \$0.10 per share; authorized 10,000 shares, issued 3,420 shares | 342 | 342 |
| Paid-in capital | 36,447 | 35,945 |
| Accumulated other comprehensive income | 215 | 283 |
| Retained earnings | 224,810 | 219,516 |
| Treasury shares, 1,600 at March 31, 2016 and 1,596 at December 31, 2015, at cost | (113,262) | (111,988) |
| Total stockholders' equity | 148,552 | 144,098 |
| Total liabilities and stockholders' equity | \$170,187 | \$164,336 |

The accompanying notes are an integral part of these financial statements.

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

| | Three Months Ended March 31, | |
|--|---------------------------------|-----------|
| | 2016 | 2015 |
| | (in thousands) | |
| Cash flows from operating activities: | | |
| Net income | \$6,945 | \$7,602 |
| Adjustments to reconcile net income to net cash provided by operating activities: | | |
| Depreciation and amortization | 2,212 | 2,170 |
| Deferred income taxes | (168) | 412 |
| Stock-based compensation | 491 | 405 |
| Impairment of investment | 345 | -- |
| Net change in accrued interest, premiums, and discounts on investments | 5 | (98) |
| | 9,830 | 10,491 |
| Changes in operating assets and liabilities: | | |
| Accounts receivable | (5,097) | (4,445) |
| Inventories | (697) | 1,275 |
| Prepaid expenses | 1,562 | 3,320 |
| Other non-current assets | (62) | (166) |
| Accounts payable and accrued liabilities | (487) | (3,280) |
| Accrued income and other taxes | 2,209 | 454 |
| Other non-current liabilities | (120) | 96 |
| | 7,138 | 7,745 |
| Cash flows from investing activities: | | |
| Property, plant and equipment additions | (2,947) | (2,661) |
| Purchase of investments | (1,676) | -- |
| Proceeds from maturities of investments | -- | 8,400 |
| | (4,623) | 5,739 |
| Cash flows from financing activities: | | |
| Purchase of treasury stock | (1,276) | (16,985) |
| Dividends paid | (1,638) | (1,403) |
| | (2,914) | (18,388) |
| Net change in cash and cash equivalents | (399) | (4,904) |
| Cash and cash equivalents at beginning of period | 28,346 | 20,775 |
| Cash and cash equivalents at end of period | \$27,947 | \$15,871 |
| Cash paid for: | | |
| Income taxes | \$104 | \$87 |

The accompanying notes are an integral part of these financial statements.

ATRION CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited)

| | Common Stock | | Treasury Stock | | Additional | Accumulated | Retained | |
|---------------------------------------|--------------|--------|----------------|--------------|------------|---------------|------------|------------|
| | Shares | Amount | Shares | Amount | Paid-in | Other | Earnings | Total |
| | Outstanding | | | | Capital | Comprehensive | | |
| Balances, December 31, 2015 | 1,824 | \$ 342 | 1,596 | \$ (111,988) | \$ 35,945 | \$ 283 | \$ 219,516 | \$ 144,098 |
| Net income | | | | | | | 6,945 | 6,945 |
| Other comprehensive income | | | | | | (68) | | (68) |
| Stock-based compensation transactions | | | | | 502 | | | 502 |
| Purchase of treasury stock | (4) | | 4 | (1,274) | | | | (1,274) |
| Dividends | | | | | | | (1,651) | (1,651) |
| Balances, March 31, 2016 | 1,820 | \$ 342 | 1,600 | \$ (113,262) | \$ 36,447 | \$ 215 | \$ 224,810 | \$ 148,552 |

The accompanying notes are an integral part of these financial statements.

ATRION CORPORATION AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. No shares of common stock for the quarters ended March 31, 2016 or March 31, 2015 were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive.

(4) Investments

As of March 31, 2016, we held certain investments that are required to be measured for disclosure purposes at fair value on a recurring basis. These investments are considered Level 2 investments and are all considered to be held-to-maturity securities. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets. The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of March 31, 2016 (in thousands):

| | Cost | Gross Unrealized | | Fair Value |
|--------------------------------|----------|------------------|--------|------------|
| | | Gains | Losses | |
| Short-term Investments: | | | | |
| Corporate bonds | \$ 39 | \$ -- | \$ -- | \$ 39 |
| Long-term Investments | | | | |
| Corporate bonds | \$ 5,210 | \$ 1 | \$ -- | \$ 5,211 |

The amortized cost and fair value of our investments, and the related gross unrealized gains and losses, were as follows as of December 31, 2015 (in thousands):

| | Cost | Gross Unrealized | | Fair Value |
|--------------------------------|----------|------------------|----------|------------|
| | | Gains | Losses | |
| Short-term Investments: | | | | |
| Corporate bonds | \$ 44 | \$ -- | \$ -- | \$ 44 |
| Long-term Investments | | | | |
| Corporate bonds | \$ 5,555 | \$ -- | \$ (30) | \$ 5,525 |

The above long-term corporate bonds represent investments in two issuers at March 31, 2016. One of these bonds experienced a significant decline in market value resulting from a major economic decline in its industry. In the fourth quarter of 2015, we determined based upon disclosures by the issuer that, more likely than not, we would be required to sell or exchange the bond before recovery of its amortized cost. Therefore, we then recorded an impairment loss on this long-term corporate bond reducing the carrying value of the bond to its market value at December 31, 2015. In the first quarter of 2016, this corporate bond experienced further declines. Therefore, we recorded an impairment loss on this bond of \$345,000 reducing the carrying value of the bond to its market value at March 31, 2016. This loss is reported as other income (expense) on our income statement. The investment in the other issuer has not been in a loss position since December 31, 2015. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest our investment may not be recoverable.

ATRION CORPORATION AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (Unaudited)

At March 31, 2016, the length of time until maturity of these securities ranged from 32 months to 43 months.

The cost and fair value of our investments that are being accounted for as available-for-sale securities, and the related gross unrealized gain reflected in accumulated other comprehensive income, were as follows as of the dates shown below (in thousands):

| | Cost | Gross Unrealized | | Fair value |
|------------------------|----------|------------------|--------|------------|
| | | Gains | Losses | |
| As of March 31, 2016: | | | | |
| Long-term Investments: | | | | |
| Equity investments | \$ 5,552 | \$ 330 | \$ -- | \$ 5,882 |

| | Cost | Gross Unrealized | | Fair value |
|--------------------------|----------|------------------|--------|------------|
| | | Gains | Losses | |
| As of December 31, 2015: | | | | |
| Long-term Investments: | | | | |
| Equity investments | \$ 3,876 | \$ 435 | \$ -- | \$ 4311 |

(5) Recent Accounting Pronouncements

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The objective of this update is to simplify several aspects of the accounting for employee share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This ASU is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The main objective of this update is to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. The new guidance addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. This ASU is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes (ASU 2015-17) which requires that deferred tax liabilities and assets be classified as noncurrent on the balance sheet. The current requirement that deferred tax liabilities and assets of a tax-paying component of an entity be offset and presented as a single amount is not affected by this guidance. ASU 2015-17 is effective for annual and interim periods beginning after December 15, 2016 but early application is permitted and the guidance may be applied either prospectively to all deferred tax liabilities and assets or retrospectively to all periods presented. We do not anticipate a material impact on our consolidated financial statements at the time of adoption of this new standard.

ATRION CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09). ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in United States Generally Accepted Accounting Principles when it becomes effective. In July 2015, the FASB voted to delay the effective date of ASU 2014-09 by one year, making it effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, with early adoption permitted as of the original effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We are evaluating the effect that ASU 2014-09 will have on our consolidated financial statements and related disclosures. We have not yet selected a transition method nor have we determined the impact of ASU 2014-09 on our consolidated financial statements.

From time to time, new accounting standards updates applicable to us are issued by the Financial Accounting Standards Board, or FASB, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards updates that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include valves and inflation devices used in marine and aviation safety products.

Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service and delivery time.

Our strategy is to provide a broad selection of products in the areas of our expertise. Research and development efforts are focused on improving current products and developing highly-engineered products that meet customer needs and serve niche markets with meaningful sales potential. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce or pay off indebtedness, to fund capital expenditures, to repurchase stock and to pay dividends.

Our strategic objective is to further enhance our position in our served markets by:

- Focusing on customer needs;
- Expanding existing product lines and developing new products;
- Maintaining a culture of controlling cost; and
- Preserving and fostering a collaborative, entrepreneurial management structure.

For the three months ended March 31, 2016, we reported revenues of \$36.2 million, operating income of \$10.5 million and net income of \$6.9 million, down 5.5 percent, 8.9 percent and 8.6 percent, respectively, from the three months ended March 31, 2015.

Results for the three months ended March 31, 2016

Consolidated net income totaled \$6.9 million, or \$3.81 per basic and \$3.76 per diluted share, in the first quarter of 2016. This is compared with consolidated net income of \$7.6 million, or \$4.05 per basic and \$4.01 per diluted share, in the first quarter of 2015. The income per basic share computations are based on weighted average basic shares outstanding of 1,823,000 in the 2016 period and 1,875,000 in the 2015 period. The income per diluted share computations are based on weighted average diluted shares outstanding of 1,849,000 in the 2016 period and 1,895,000 in the 2015 period.

Consolidated revenues of \$36.2 million for the first quarter of 2016 were 5.5 percent lower than revenues of \$38.3 million for the first quarter of 2015. Revenues were impacted by the strong U.S. dollar, as well as by the commoditization of an ophthalmic product.

Revenues by product line were as follows (in thousands):

| | Three Months ended March 31, | |
|----------------|---------------------------------|-----------|
| | 2016 | 2015 |
| Fluid Delivery | \$ 15,689 | \$ 15,894 |
| Cardiovascular | 11,714 | 11,936 |
| Ophthalmology | 3,471 | 5,199 |
| Other | 5,341 | 5,295 |
| Total | \$ 36,215 | \$ 38,324 |

Cost of goods sold of \$18.7 million for the first quarter of 2016 was \$1.2 million lower than in the comparable 2015 period. The primary contributors to the decrease in our cost of goods sold were decreased sales, the impact of continued cost improvement initiatives and the suspension of the medical device excise tax. In December 2015, as part of the Omnibus Appropriations Act, collection of the medical device excise tax was suspended for 2016 and 2017. Our cost of goods sold in the first quarter of 2016 was 51.5 percent of revenues compared with 51.7 percent of revenues in the first quarter of 2015.

Gross profit of \$17.6 million in the first quarter of 2016 was \$959,000, or 5.2 percent, lower than in the comparable 2015 period. Our gross profit percentage in the first quarter of 2016 was 48.5 percent of revenues compared with 48.3 percent of revenues in the first quarter of 2015. The increase in gross profit percentage in the 2016 period compared to the 2015 period was primarily attributable to the suspension of the medical device excise tax.

Our first quarter 2016 operating expenses of \$7.1 million were \$62,000 higher than the operating expenses for the first quarter of 2015. This increase was comprised of a \$215,000 increase in Selling expenses partially offset by a \$144,000 decrease in Research and Development, or R&D, expenses and a \$9,000 decrease in General and Administrative, or G&A, expenses. The increase in Selling expenses was primarily attributable to market research costs, compensation and outside services. The decrease in R&D costs was primarily attributable to decreased supplies and outside services. The decrease in G&A expenses for the first quarter of 2016 was primarily attributable to decreased compensation partially offset by increased outside services and depreciation.

Operating income in the first quarter of 2016 decreased \$1.0 million to \$10.5 million, an 8.9 percent decrease from our operating income in the quarter ended March 31, 2015. Operating income was 28.9 percent of revenues in the first quarter of 2016 compared to 30.0 percent of revenues in the first quarter of 2015. The major contributor to the decrease in operating income for the first quarter of 2016 was the previously mentioned decrease in revenues.

Interest income in the first quarter of 2016 was \$123,000, compared with \$177,000 in the first quarter of 2015. Reduced levels of investments and lower interest rates were the primary reasons for the reductions in 2016.

Other income (expense) is primarily related to an impairment loss on one of our long-term corporate bonds. In the fourth quarter of 2015, we determined that, more likely than not, we would be required to sell or exchange the bond before recovery of its amortized cost. Therefore, we recorded an impairment on this long-term corporate bond reducing the carrying value of the bond to its market value at December 31, 2015. In the first quarter of 2016, the market value of this corporate bond experienced further declines. Therefore, we recorded an impairment loss on this bond of \$345,000 reducing the carrying value of the bond to its market value at March 31, 2016.

Income tax expense for the first quarter of 2016 was \$3.3 million compared to income tax expense of \$4.1 million for the same period in the prior year. The effective tax rate for the first quarter of 2016 was 32.2 percent, compared with 34.8 percent for the first quarter of 2015. The lower first quarter 2016 effective rate benefited primarily from the extension of the R&D tax credit in December 2015. The R&D tax credit was extended during the fourth quarter of 2015, and the unavailability of the R&D tax credits for the first quarter of 2015 resulted in a higher effective tax rate in that quarter. We expect the effective tax rate for the remainder of 2016 to be approximately 33.5 percent.

Liquidity and Capital Resources

We have a \$40.0 million revolving credit facility with a money center bank that can be utilized for the funding of operations and for major capital projects or acquisitions, subject to certain limitations and restrictions. Borrowings under the credit facility bear interest that is payable monthly at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent. Effective June 11, 2015, our revolving credit facility was amended to extend the date until which the lender is obligated to make advances under the revolving line of credit to October 1, 2021 and, assuming an event of default is not then existing, we can convert outstanding advances under the revolving line of credit to term loans with a term of up to two years. We had no outstanding borrowings under our credit facility at March 31, 2016 or at December 31, 2015. The credit facility contains various restrictive covenants, none of which is expected to impact our liquidity or capital resources. At March 31, 2016, we were in compliance with all financial covenants.

At March 31, 2016, we had a total of \$39.1 million in cash and cash equivalents, short-term investments and long-term investments, an increase of \$822,000 from December 31, 2015.

Cash flows from operating activities for the three months ended March 31, 2016 were \$7.1 million and primarily consisted of net income of \$6.9 million and non-cash items of \$2.9 million, partially offset by a net decrease in operating assets and liabilities of \$2.7 million. During the first quarter of 2016, we expended \$2.9 million for the addition of property and equipment, \$1.7 for the purchase of investments, \$1.3 million for purchases of treasury stock under our stock repurchase program and \$1.6 million for dividends.

At March 31, 2016, we had working capital of \$71.1 million, including \$27.9 million in cash and cash equivalents and \$39,000 in short-term investments. The \$2.1 million increase in working capital during the first quarter of 2016 was primarily attributable to increases in accounts receivable and inventories. This increase was partially offset by increases in accrued income and other taxes and decreases in prepaid expenses. The increase in accounts receivable was primarily attributable to increased revenues for the first quarter of 2016 as compared with the fourth quarter of 2015. The increase in inventories was primarily related to higher safety stock levels necessary to support anticipated revenues. The decrease in prepaid expenses was primarily attributable to federal income tax payments. The increase in accrued income and other taxes was primarily attributable to current federal tax obligations.

We believe that our \$39.1 million in cash, cash equivalents, short-term investments and long-term investments, along with cash flows from operations and available borrowings of up to \$40.0 million under our credit facility, will be sufficient to fund our cash requirements for at least the foreseeable future. We believe that our strong financial position would allow us to access equity or debt financing should that be necessary. Additionally, we believe that our cash and cash equivalents, short-term investments and long-term investments, as a whole, will continue to increase during the remainder of 2016.

Forward-Looking Statements

Statements in this Management's Discussion and Analysis and elsewhere in this Quarterly Report on Form 10-Q that are forward looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our effective tax rate for the remainder of 2016, our ability to fund our cash requirements for the foreseeable future with our current assets, long-term investments, cash flow and borrowings under the credit facility, our access to equity and debt financing, and the increase in cash, cash equivalents, and investments in the remainder of 2016. Words such as "expects," "believes," "anticipates," "intends," "should," "plans," and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For the quarter ended March 31, 2016, we did not experience any material changes in market risk exposures that affect the quantitative and qualitative disclosures presented in our 2015 Form 10-K.

Item 4. Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2016. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are effective. There were no changes in our internal control over financial reporting for the quarter ended March 31, 2016 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be involved in claims or litigation that arise in the normal course of business. We are not currently a party to any legal proceedings, which, if decided adversely, would have a material adverse effect on our business, financial condition, or results of operations.

Item 1A. Risk Factors

There were no material changes to the risk factors disclosed in our 2015 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The table below sets forth information with respect to our purchases of our common stock during each of the three months in the period ended March 31, 2016.

| Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (1) |
|----------------------------|---|------------------------------------|--|---|
| 1/1/2016 through 1/31/2016 | - | - | - | - |
| 2/1/2016 through 2/28/2016 | - | - | - | - |
| 3/1/2016 through 3/31/2016 | 3,427 | \$ 372.24 | 3,427 | 231,355 |
| Total | 3,427 | \$ 372.24 | 3,427 | 231,355 |

(1) On May 21, 2015, our Board of Directors approved a new stock repurchase program pursuant to which we can repurchase up to 250,000 shares of our common stock from time to time in open market or privately-negotiated transactions. Our stock repurchase program has no expiration date but may be terminated by our Board of Directors at any time.

Item 6. Exhibits

| Exhibit Number | Description |
|---|--|
| 31.1 | Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer |
| 31.2 | Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer |
| 32.1 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002 |
| 31.2 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002 |
| 101.INS XBRL Instance Document | |
| 101.SCH XBRL Taxonomy Extension Schema Document | |
| 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF XBRL Taxonomy Extension Definition Linkbase Document | |

101.LAB XBRL Taxonomy Extension Label Linkbase Document

101.PRE XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Atrion Corporation

Date: May 4, 2016

By: /s/ David A. Battat
David A. Battat
President and
Chief Executive Officer

Date: May 4, 2016

By: /s/ Jeffery Strickland
Jeffery Strickland
Vice President and
Chief Financial Officer
(Principal Accounting and Financial
Officer)

Exhibit Index

| Exhibit Number | Description |
|--|--|
| 31.1 | Sarbanes-Oxley Act Section 302 Certification of Chief Executive Officer |
| 31.2 | Sarbanes-Oxley Act Section 302 Certification of Chief Financial Officer |
| 32.1 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002 |
| 31.2 | Certification Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To Section 906 of The Sarbanes – Oxley Act Of 2002 |
| 101.INS XBRL Instance Document | |
| 101.SCH XBRL Taxonomy Extension Schema Document | |
| 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document | |